Egle Therapeutics nabs $46M as it looks to push into the clinic with next-gen Tregs platformnews2021-10-22T11:28:14+00:00October 22nd, 2021|FierceBiotech|
Metacrine shares halved as NASH program nixed on mixed bag data and early safety issuenews2021-10-22T10:32:14+00:00October 22nd, 2021|FierceBiotech|
Could cancer drugs address a hard-to-treat lung disease? Researchers say 2 look promisingnews2021-10-21T21:51:31+00:00October 21st, 2021|FierceBiotech|
Ventyx nabs a $152M upsized IPO to challenge BMS’ Zeposia—and a backer with intimate knowledge of its rivalnews2021-10-21T13:00:02+00:00October 21st, 2021|FierceBiotech|
VCs back Leucid to trial CAR-T twist in ovarian cancer patientsnews2021-10-21T12:09:58+00:00October 21st, 2021|FierceBiotech|
Menarini, chased by 3 Big Pharmas, records win in breast cancer phase 3, plots path to FDAnews2021-10-21T10:12:22+00:00October 21st, 2021|FierceBiotech|
FDA slaps clinical hold on AstraZeneca cancer drug amid heart safety scare in combo testnews2021-10-20T17:59:32+00:00October 20th, 2021|FierceBiotech|
Chase, after selling last biotech to Allergan, gets cash to start pivotal trials in depression, Parkinson’s news2021-10-20T12:43:25+00:00October 20th, 2021|FierceBiotech|
Takeda crashes out of Wave discovery pact at cost of $23Mnews2021-10-20T11:51:22+00:00October 20th, 2021|FierceBiotech|
Princeton and MIT gene-editing pioneers uncover clues for improving CRISPR and other toolsnews2021-10-20T10:20:12+00:00October 20th, 2021|FierceBiotech|
